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David Rowell1,2*, Louisa G Gordon1,4, Catherine M Olsen3,4 and David C Whiteman3,4Abstract
The medical record is a repository of clinical data, which can greatly enhance the quality of health and healthcare
analysis. Administrative data are collected for the purpose of billing and reimbursement, and are valued by health
researchers because the data are routinely audited to maintain accurate financial records. However, the quantity of
incorporated clinical data can be variable. In this paper we reconstruct the medical record from health service
invoices to estimate the cost of treating keratinocytic cancer (KC). The data from an epidemiological survey were
linked to an administrative data set supplied by the national health insurer. A matched sampling technique with
multivariable analysis was used to estimate cost. A KC treatment was identified with 42 service codes which
explicitly nominated treatment of a KC. Algorithms identifying comorbities potentially correlated with KC were
constructed from the service codes. The annual cost of a KC treatment was estimated to be AU$667 per individual.
The average cost of explicit KC treatments was AU$231, while the cost of generic procedures used to treat KC was
AU$436. Our ability to accurately control for the medical history enabled our analysis to quantify and describe the
constituent costs of KC treatment.
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Empirical analysis in healthcare can be enhanced by
controlling for the confounding effects of comorbidities
documented within a patient’s medical record. A pa-
tient’s medical history can be obtained by direct inter-
view or interrogation of their medical record. However,
self-reported medical histories can be subject to a re-
porting bias, while review of the medical record may be
unfeasible or costly. There is a growing appreciation of
the benefits of using administrative data to conduct
health research [1-3]. Many health insurers, both public
and private, generate large datasets for the purpose of
either reimbursing physicians or invoicing patients.* Correspondence: d.rowell@uq.edu.au
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in any medium, provided the original work is pAlthough not designed for research, these administrative
data, which include item codes identifying discrete epi-
sodes of care, are a potentially rich source of clinical
information.
In this paper, our aim is to reconstruct a patient’s
medical history from the service codes contained within
an administrative dataset, to facilitate the estimation of
the cost of treating the non-melanoma skin cancers (and
which are more accurately described as keratinocyte
cancers (KC)). Keratinocyte cancers, which comprise
both basal cell carcinomas (BCC) and squamous cell
carcinoma (SCC), are cancers with high incidence but
low mortality. Worldwide, KC are the most prevalent
cancers affecting white-skinned individuals and their
incidence is rising rapidly in many countries [4]. High
reported incidence rates of KC in Australia (1,170 per
100,000) [5] and the United States (233 per 100,000) [6]
ensure that these cancers remain the most costly and
fifth most costly to treat in Australia [7] and the United
States [8], respectively. However, due to their lown Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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complete or non-existent reporting of KC [4,9]. Therefore,
the analysis of administrative data may be particularly
useful for health service research of diseases such as
KC, where conventional data sources may otherwise be
incomplete.
Our literature review identified nine studies that esti-
mated the cost of treating KC using administrative data
[7,8,10-16]. Although each study analysed a different
dataset, their methods were broadly similar. Typically,
they identified an episode of treatment for KC within
their data. They then ascribed a mean cost per KC
episode before reporting an aggregate cost, for their jur-
isdiction of interest. However, there was significant het-
erogeneity with respect to how KC treatments were
defined and costed. For example Souza et al. [17] relied
on “expert opinion” to define a KC treatment. Data from
the Brazilian National Health Service and medical costs
supplied by the Brazilian Medical Association were used
to estimate aggregate costs. An Australian study pub-
lished by Fransen et al. analysed an administrative data-
set obtained from the national health insurer, Medicare
Australia [7]. These data included a unique item code
for each medical service delivered. A treatment for KC
was identified if one of 37 item codes, which denoted ex-
cision of a BCC or SCC, were identified within the data.
The corresponding costs were summed and reported.
However, the costs of ancillary services such as histology
or pharmaceuticals were not included nor were the costs
of attendance fees.
The surveyed literature almost entirely reports average
and aggregate costs. Three European studies [10-12]
identified a KC using the International Classification of
Diseases (ICD) codes and costs of treatment were esti-
mated by using national Diagnostic Related Group
(DRG) cost weights. Outpatient costs were included in
an ad hoc manner, using sub-samples of outpatient cost
data. The three US studies [8,14,18] used data collected
for the Medicare Current Beneficiary Survey (MCBS)
1992–95 to derive cost estimates for KC. Data from each
Medicare claim was linked to the appropriate specialty
[14] and costs summed and reported. While these costing
methods were no doubt sound, simply reporting an aggre-
gate cost provides little opportunity for researchers and
policy makers to further integrate these estimates. As the
focus of these studies tended to be on the procedure
rather than the individual questions concerning who
is consuming which KC treatments remained largely
unanswered.
We could identify one study, which employed a differ-
ent method. Bentzen et al. [16] estimate the cost of
treating KC in Denmark. The Danish National Patient
Register tracks all inpatient and outpatient health costs.
A KC was identified using ICD codes. All individualstreated for a KC in the period 2004 to 2008 were
matched to a set of controls (at a ratio of 1:4) on four
criteria (age, sex, civil status and residence). The costs of
treating KC were calculated as the average annual excess
costs per year for patients after diagnosis relative to the
matched control cohort. The principal strength of the
paper by Bentzen et al. [16] lay in its capacity to analyse
patient records, which linked cost and demographic
data. While KC incidence was identified by ICD code,
the cost of a treatment was not predetermined. Instead
Bentzen et al. [16] estimated the cost of treating KC
conditional upon a set of demographic controls. An ad-
vantage of this approach is that a description of treat-
ment costs can be developed. The principal limitation
was that Bentzen et al. [16] only controlled for age, sex,
civil status and residence. Human disease can be corre-
lated for a variety of genetic, environmental and social
reasons. If available, controls for medical history may
have been beneficial.
In this paper, we derive a set of dichotomous variables
from treatments documented in an administrative data-
set to capture the medical history. Our aims were two-
fold. Firstly, we control for cost of treating comorbid
disease to report an estimate the cost of KC treatment.
Secondly, we identified and classified the medical treat-
ments utilised by patients with KC. Controlling for med-
ical history can not only result in more accurate measures




In 2011, the QSkin study enrolled 43,794 individuals
aged 40 to 69 years selected at random from the
Queensland electoral roll [19,20]. Overall, 46% of the
respondents were male with a mean age of 56 years [19].
The respondents reported their level of sun exposure,
skin phenotype, history of skin cancer, demographic
and socio-economic characteristics [19]. Ethical ap-
proval for the study was received from the QIMR
Berghofer Institute of Medical Research Human Research
Ethics Committee and the Department of Health. Consent
was obtained to link survey data supplied by the respond-
ent to individual level cost data obtained from two publi-
cally funded health programs administered by Medicare
Australia, the Pharmaceutical Benefits Scheme (PBS) and
the Medical Benefits Scheme (MBS). The PBS subsidises
the cost of approved pharmaceuticals. The MBS subsidises
(i) fee-for-service medical care provided by GPs and spe-
cialist physicians delivered in their private consulting
rooms and (ii) medical care provided to private patients
treated in private and public hospitals. However, the MBS
excludes medical services provided to public inpatients.
Other inpatient costs (private and public) not included in
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health and ancillary services), hospital consumables, ad-
ministrative overheads and capital depreciation.
Thus, the proportion of the total KC treatment costs
captured by this sub-set of healthcare costs identifiable
by a MBS item number is uncertain. A national survey
of individuals treated for KC (n = 2502) in 2002 reported
that 51.1% respondents were treated by general practi-
tioners, 17.6% by dermatologists, 10.3% in skin cancer
clinics, 5.9% by plastic surgeons, 3.4% other surgeons
and 1% other and 9.2% not stated [21]. However, only
1.6% of respondents indicated that their last KC treatment
was conducted in hospital [21]. While these categories are
(i) not necessarily mutually exclusive (e.g., plastic surgery
can be conducted in a hospital), and (ii) report treatments
not costs, it is likely that medical treatments denoted by
an MBS item number comprise a very high proportion of
total KC treatment costs.
A sub-sample comprised of 2,000 randomly selected
individuals with KC matched 1:1 on gender and 5-year
age categories, to a group of controls. KC was identified
by 42 MBS codesa, which unequivocally indicated a
treatment for a BCC or SCC (see Table 1). Data cleaning
identified inconsistencies in 0.4% of the cases and 11.95%
of the controls, which were subsequently removed. The
final sample of 3,753 individuals was comprised of 1,992
cases with KC and 1,761 controls. After matching the case
and control cohorts contained an equal proportion of
males and females. Individuals with KC were slightly older
(57.2 years versus 55.7 years) more likely to be white
(95.8% versus 92.3%), born in Australia (85.2% versus
79.6%), less likely to be employed full-time (39.8% versus
45.5%) and not have private health insurance (73.6%
versus 67.6%).
Theoretical model
Conceptually an individual with KC could incur three
categories of medical costs related to the treatment of
KC, two categories of direct treatment costs and one
category for related costs. Category 1 costs refer to those
procedures, which explicitly identify the treatment of a
KC (i.e. the 42 MBS codes detailed above). Category 2
costs refer to non-specific medical treatments, which
could also apply to the overall clinical management of
KC, for example histopathology, or treatment with anti-
biotics. Thus, the total cost of treating KC is given by
the sum of Category 1 and 2 costs. Category 3 costs
refer to the treatment of comorbidities correlated with
incidence of KC (e.g. melanoma).
The existence of correlated diseases that generate
Category 3 costs could occur because of physiological,
environmental, or psychosocial processes. KC is known
to be correlated with other cancers [13,22]. Environmental
factors such as ultraviolet (UV) radiation are positivelycorrelated with melanoma [23,24] and KC [25]. Negative
correlations may also exist, since UV radiation is respon-
sible for the synthesis of vitamin D. Nowson et al. [26]
have stated that Vitamin D deficiency is correlated with
several diseases including heart disease [27], breast and
colon cancer [28], autoimmune diseases such as multiple
sclerosis [29], osteoporosis [30,31] and depression [32].
Other implicated diseases include Parkinson’s disease [33],
tuberculosis [34] and infectious diseases [31]. Psychosocial
factors could affect an individual’s capacity to implement
disease prevention measures. Individuals who ignore pub-
lic health campaigns to mitigate KC might also disregard
other disease prevention initiatives.
Empirical model
To control for the potentially confounding effects of the
cost of treating correlated comorbidities the following
empirical model was estimated.
C ¼ f KC;Rx;Hx;G; Að Þ
Where
C ¼ MBSSubsidy þ MBSCo−payment
 
þ PBSSubsidy þ PBSCo−payment
 
KC ¼ 1 if one of 42 Category 1 treatments
Rx ¼ 16 concurrent treatments
Hx ¼ 16past treatments
G ¼ Gender
A ¼ Age
The dependent variable Cost, measured in 2012
Australian dollars, was the sum of all MBS and PBS
government subsidies and patient co-payments for ser-
vices utilised from July 2011 to June 2012. Our explana-
tory variable of interest KC was a dichotomous variable
equal to one if the participant received one of 42 identified
treatments listed in Table 1.
The principal requirement of our empirical model was
that it controlled for the cost of concurrent treatments.
The vector Rx, which contained 16 dichotomous variables
indicating the treatment of; three autoimmune diseases
(asthma, rheumatoid arthritis and multiple sclerosis), two
mental illnesses (depression and anxiety), cardiovascular
disease and two associated risk factors (hypertension and
hyperlipidaemia), four cancers (melanoma, breast, prostate
and colorectal), osteoporosis, Parkinson’s disease, tubercu-
losis and bronchitis, was constructed from item codes
supplied by Medicare Australia.
The Merck Manual [35] was reviewed to formulate
a complete list of all diagnostic, medical, surgical and
pharmacological treatments used to managed each co-
morbidity of interest. A search of the MBS [36] and
PBS [37] websites was conducted to match each iden-
tified treatment to its corresponding item codes.
Table 1 Observed category 1 costs
Medical benefits scheme item description MBS code Freq. Mean (AU$) Total (AU$)
Diagnostic biopsy of skin or mucous membrane, specimen sent for biopsy 30071 1956 49 96,351
Removal of malignant neoplasm of skin by serial curettage or carbon
dioxide laser excision-ablation: < 10 lesions
30196 433 96 41,590
Removal of malignant neoplasm of skin by serial curettage or carbon
dioxide laser excision-ablation: > 10 lesions
30197 8 680 5,438
Removal of malignant neoplasm of skin by cryotherapy: <10 lesions 30202 121 42 5,082
Removal of malignant neoplasm of skin by cryotherapy: > 10 lesions 30203 16 145 2,328
Removal of malignant neoplasm of skin and cartilage by cryotherapy: > 10 lesions 30205 0 0 0
Mircographically controlled serial excision of skin tumour with histological
examination: < 6 lesions
31000 15 826 12,383
Mircographically controlled serial excision of skin tumour with histological
examination: 7–12 lesions
31001 6 1,111 6,667
Mircographically controlled serial excision of skin tumour with histological
examination: > 13 lesions
31002 2 1,225 2,451
Removal from nose, eyelid, lip, ear, digit or genitalia by surgical excision
Removal of BCC or SCC with malignancy confirmed: < 10 mm diameter 31255 169 183 30,950
Removal of residual BCC or SCC by original GP, specimen sent to histology:
Original tumour < 10 mm diameter
31256 15 165 2,475
Removal of residual BCC or SCC by non-original GP, specimen sent to histology:
Original tumour < 10 mm diameter
31257 3 264 791
Removal of recurrent BCC or SCC, malignancy confirmed by histology:
Original tumour < 10 mm diameter
31258 1 185 185
Removal of BCC or SCC with malignancy confirmed: >10 mm diameter 31260 46 218 10,038
Removal of residual BCC or SCC by original GP, specimen sent to histology:
Original tumour >10 mm diameter
31261 6 291 1,746
Removal of residual BCC or SCC by non-original GP, specimen sent to histology:
Original tumour > 10 mm diameter
31262 1 422 422
Removal of recurrent BCC or SCC, malignancy confirmed by histology:
Original tumour > 10 mm diameter
31263 0 0 0
Removal from face, neck (anterior to the sternomastoid muscles) or lower
leg (mid-calf to ankle) by surgical excision
Removal of BCC or SCC, malignancy confirmed by histology, <10 mm diameter 31265 338 165 55,710
Removal of residual BCC or SCC, by original GP, specimen sent to histology:
Original tumour <10 mm diameter
31266 12 177 2,126
Removal of residual BCC or SCC, by non-original GP, specimen sent to histology:
Original tumour <10 mm diameter
31267 1 154 154
Removal of recurrent BCC or SCC, malignancy confirmed by histology:
Original tumour >10 mm diameter
31268 1 154 154
Removal of BCC or SCC with malignancy confirmed: 10-20 mm diameter 31270 128 213 27,276
Removal of residual BCC or SCC by original GP, specimen sent to histology:
Original tumour 10-20 mm diameter
31271 1 106 106
Removal of residual BCC or SCC by non-original GP, specimen sent to histology:
Original tumour 10-20 mm diameter
31272 0 0 0
Removal of recurrent, BCC or SCC, malignancy confirmed: Original tumour
10-20 mm diameter
31273 0 0 0
Removal of BCC or SCC, malignancy confirmed: >20 mm diameter 31275 25 246 6,158
Removal of residual BCC or SCC, by original GP, specimen sent to histology:
Original tumour >20 mm diameter
31276 2 188 376
Removal of residual BCC or SCC, by non-original GP; Original tumour >20 mm diameter 31277 1 101 101
Removal of recurrent BCC or SCC, malignancy confirmed: Original tumour > 20 mm diameter 31278 0 0 0
Removal from other body areas by surgical excision
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Removal of BCC or SCC, malignancy confirmed by histology, <10 mm diameter 31280 620 144 89,155
Removal of residual BCC or SCC, by original GP, specimen sent to histology:
Original tumour <10 mm diameter
31281 7 171 1,197
Removal of residual BCC or SCC, by non-original GP, specimen sent to histology:
Original tumour <10 mm diameter
31282 2 141 282
Removal of recurrent BCC or SCC, malignancy confirmed by histology: Original
tumour >10 mm diameter
31283 1 131 131
Removal of BCC or SCC with malignancy confirmed: 10-20 mm diameter 31285 267 179 47,706
Removal of residual BCC or SCC by original GP, specimen sent to histology:
Original tumour 10-20 mm diameter
31286 2 133 267
Removal of residual BCC or SCC by non-original GP, specimen sent to histology:
Original tumour 10-20 mm diameter
31287 2 178 355
Removal of recurrent, BCC or SCC, malignancy confirmed: Original tumour 10-20 mm diameter 31288 0 0 0
Removal of BCC or SCC, malignancy confirmed: >20 mm diameter 31290 30 226 6,782
Removal of residual BCC or SCC, by original GP, specimen sent to histology: Original
tumour >20 mm diameter
31291 1 201 201
Removal of residual BCC or SCC, by non-original GP: Original tumour >20 mm diameter 31292 2 355 710
Removal of recurrent BCC or SCC, malignancy confirmed: Original tumour > 20 mm diameter 31293 0 0 0
Removal of recurrent BCC or SCC, by non-original GP, malignancy confirmed:
Tumour size unspecified.
31295 6 304 1,822
Totals 4247 459,664
Note:
(i) KC < 10 mm (31255, 31256, 31258, 31265, 31266, 31267, 321280, 31281).
(ii) KC > 20 mm (31275, 31277, 31290).
iii) KC 10-20 mm (31270, 31285, 31287).
(iv) KC > 10 mm (31260, 31261, 31262) [Removed from nose, eyelid, lip, ear, digit or genitalia].
(v) Unspecified size (30071, 31096, 30202, 30203).
Abbreviations: Basal Cell Carcinoma (BCC), Squamous Cell Carcinoma (SCC), General Practitioner (GP).
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tion algorithms. While not all treatments could uniquely
identify a diagnosis, many treatments do indicate a diag-
nosis. For example, antihypertensive medications are indi-
cative of treatment for hypertension and antidepressants
are indicative of treatment for depression. We exercised
our clinical judgement to ensure that all included item
codes could identify a clinical diagnosis. Nonspecific treat-
ments were removed from the algorithms. For example,
morphine, which is sometimes used to treat angina, was
not used as an indicator of cardiovascular disease. An
itemised list of the 1500 MBS and PBS item codes used to
identify the 16 comorbidities are attached in Additional
file 1. Comorbidity frequencies are reported in the
appendix.
The QSkin survey collected information on co-
morbidities as free text. The respondents could report
up to two medical conditions that required treatment
from a specialist doctor and two cancers (other than
skin cancer). The written responses were analysed and
used to generate Hx, a vector of 16 dichotomous variables
indicating previous treatment for the aforementioned
diagnoses. The vectors Rx and Hx are complementary.
The former is derived from administrative data and re-
flects concurrent medical treatment, while the latter isderived from self-reported data and captures prior medical
treatment. The costs of treating individuals who report a
medical history vis-à-vis those who do not, are likely to be
systematically different. Therefore, the vector Hx was
included to capture severity of disease.
A residual treatment category, treated for other disease,
was created to indicate if the respondent was treated for
any other disease. Thus, the reference group for our
empirical model were the 51 (1.35%) individuals who in-
curred no medical or pharmacological costs. Two demo-
graphic controls for gender and age were included in the
specification of the empirical model. The coefficient on
KC reflects the annual cost to society of 12 months of KC
treatment.
Regression using ordinary least squares (OLS) with
skewed cost data can result in heteroskedastic errors
[38] and biased variance estimates, invalidating t-statis-
tics and confidence intervals for regression coefficients
[39]. Therefore, a generalised linear model (GLM) with
the appropriate distributional family was selected using
a modified Park test [40]. The advantage of this ap-
proach is that a GLM can accommodate heteroskedasti-
city through selection of the correct distributional
family while generating predictions on the cost scale.
This approach also enables one to infer the mean cost
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obtained with a logged dependent variable [38].
Results
The average cost of all medical services utilised by the
QSkin respondents, adjusted for age and sex, was AU
$2,477. Individuals who were treated for KC consumed
an average AU$2,971, while those who were not treated
for KC consumed AU$1,918. The difference in means
was statistically significant (p = 0.01). Conceptually, the
AU$1,053 differential could be composed of Category 1,
2 and 3 costs. These costs are distilled as follows.
3.1 Category 1 costs
A Category 1 cost was defined as one any of 42 MBS
items codes, which directly identified a KC treatment
(see Table 1). Columns 1 and 2 report the MBS item de-
scription and code, respectively. Column 3 reports service
frequency. Columns 4 and 5 report the mean and total
costs. The 1,992 individuals treated for KC utilised
AU$459,664 in Category 1 services. The mean cost per
treated individual was AU$231, of which 77.7% was due to
the MBS subsidy and 22.3% was due to the co-payment.
3.2 Direct costs
Direct costs were estimated using a GLM with a log-link
function and Poisson family distribution, as determined
by modified Park test [40]. Table 2 reports the GLM co-
efficients and a set of marginal effects. The direct cost
(i.e., Category 1 and 2 services) of 12 months of KC
treatment (AU$667 (p-value < 0.01)) is the marginal
effect of a dichotomous change in KC from zero to
one, with covariates held constant at their means. When
gender and age were removed, the estimate increased to
AU$676 (p-value < 0.01) indicating our estimate is robust
with respect to these two covariates. In other specifica-
tions, dichotomous variables for education (Nil, School,
High school, Trade, Certificate and University) and
employment (Full-time, Part-time, Home duties, Student,
Retired and Other) were included to control for socio-
economic status. However, F tests for joint statistical
significance were rejected and their inclusion had no
material effect on the coefficient for KC.
The marginal effects of KC were also estimated control-
ling for comorbidity and age. Table 2, Column 4 reports
the marginal effect of a dichotomous change in KC with
each comorbidity set equal to one, and all other covariates
held constant at their mean. Hence, for individuals treated
for melanoma (n = 53), the marginal effect of 12 months
of KC treatment was AU$988. The marginal effect of KC
was estimated for each age, 40 through to 70. At age 40,
the marginal effect of 12 months of KC treatment was AU
$614. The marginal effect increased linearly, by AU$3.30
per year, to AU$713 at age 70.Cost summary
The results presented in Table 3, Column 2 summarise
the principal findings of this paper. The annual MBS
subsidy per KC treatment was AU$677 per individual.
As this estimate is a derived value, we cannot directly
differentiate between the subsidy and co-payment. If the
cost distribution was comparable to Category 1 services,
this would imply the MBS subsidy was AU$518 (77.7%)
and the co-payment AU$149 co-payment (22.3%). The
average cost of Category 1 services was AU$230 (see
Table 1 for description costs). The cost of Category 2
services used to treat KC was AU$437 (i.e. AU$667 –
AU$230). A further AU$386 (i.e. AU$1,053 – AU$667)
was spent on Category 3 services treating diseases corre-
lated with KC.
Category 2 costs
When estimated with OLS the errors were not nor-
mally distributed (Shapiro-Wilk test: W = 0.48 (p < 0.01))
and heteroskedastic (χ2 (1) = 4148.8 (p-value < 0.01)).
We estimate our model using a GLM. Category 2
costs account for 66% of the costs attributable to the
management of KC. Thus our best estimate of total
Category 2 costs related to the treatment of KC is
AU$868,512 (i.e. 1,992 * AU$436). Due to their mag-
nitude, we sought to identify those Category 2 costs
in the following way. First, the data were transformed
into wide format, such that each observation was now
a medical service. All Category 1 services were removed.
The frequencies of the residual services were cross-
tabulated with a dichotomous variable equal to one if the
service was delivered to an individual with KC and zero if
otherwise. The frequency difference, estimates the number
of Category 2 and 3 services utilised.
Freq:KC ¼ 1 – Freq:KC¼0 ¼ Category 2 services
þ Category 3 services:
Table 4 presents a summary of our findings. Column 1
lists clinical services groups, with their MBS item codes
listed in the table notes. Columns 2 and 3 list the treat-
ment frequencies for the cohorts with and without a KC
and Column 4 reports the frequency differences. The
cost of each service category is given by the product of
Columns 4 and 5 and is reported in Column 6. After
inspecting the service descriptors, we could identify
three groups of medical services, which could plausibly
be attributed to the treatment of KC. In our study, the
KC cohort consumed an additional AU$191,115 on re-
constructive surgeries, AU$167,096 on pathology and
AU$453,623 on consultation fees.
The data presented in Figure 1, summarise the analyses
presented in the paper. In our sample, the total cost of all
additional medical services consumed by people with a
Table 2 Coefficients and marginal effects for a dichotomous change in keratinocyte cancer (KC)
Variables Coefficient p-value Marginal effect of KC Covariates held constant for
calculation of marginal effects
n
Keratinocyte cancer (=0/1) 0.36 <0.01 666.5 all covariates @ mean
Other medical treatment
Treated for other disease (=0/1) −0.27 0.01 556 =1 & residual @ mean
Treated for melanoma (=0/1) 0.40 <0.01 988 =1 & residual @ mean 53
Treated for hypertension (=0/1) 0.09 0.15 719 =1 & residual @ mean 645
Treated for hyperlipidaemia (=0/1) 0.04 0.55 686 =1 & residual @ mean 1036
Treated for cardiovascular disease (=0/1) 0.56 0.00 953 =1 & residual @ mean 1342
Treated for diabetes (=0/1) 0.16 0.02 774 =1 & residual @ mean 354
Treated for breast cancer (=0/1) 0.41 <0.01 983 =1 & residual @ mean 187
Treated for colorectal cancer (=0/1) 0.36 <0.01 926 =1 & residual @ mean 279
Treated for prostate cancer (=0/1) 0.38 <0.01 952 =1 & residual @ mean 227
Treated for asthma (=0/1) 0.19 <0.01 785 =1 & residual @ mean 507
Treated for rheumatoid arthritis (=0/1) 0.30 <0.01 862 =1 & residual @ mean 546
Treated for multiple sclerosis (=0/1) 0.83 <0.01 1,522 =1 & residual @ mean 10
Treated for depression (=0/1) 0.17 <0.01 771 =1 & residual @ mean 602
Treated for anxiety (=0/1) 0.30 0.01 895 =1 & residual @ mean 118
Treated for osteoarthritis (=0/1) 0.40 <0.01 939 =1 & residual @ mean 527
Treated for Parkinson’s disease (=0/1) 0.23 0.23 840 =1 & residual @ mean 22
Treated for tuberculosis (=0/1) 0.90 < 0.01 1,626 =1 & residual @ mean 49
Treated for bronchitis (=0/1) −0.01 0.96 663 =1 & residual @ mean 85
Medical history
History of hypertension (=0/1) 0.14 0.18 - - -
History of hyperlipidaemia (=0/1) 0.21 0.39 - - -
History of cardiovascular disease (=0/1) 0.01 0.85 - - -
History of diabetes (=0/1) 0.07 0.46 - - -
History of breast cancer (=0/1) 0.21 0.06 - - -
History of colorectal cancer (=0/1) −0.29 0.03 - - -
History of prostate cancer (=0/1) 0.08 0.60 - - -
History of asthma (=0/1) 0.27 0.22 - - -
History of rheumatoid arthritis (=0/1) 0.46 0.02 - - -
History of multiple sclerosis (=0/1) 1.65 < 0.01 - - -
History of depression (=0/1) 0.04 0.75 - - -
History of anxiety (=0/1) 0.40 0.04 - - -
History of osteoarthritis (=0/1) −0.14 0.39 - - -
History of Parkinson’s disease (=0/1) 0.51 0.11 - - -
History of tuberculosis (=0/1) −0.15 0.62 - - -
History of bronchitis (=0/1) −1.03 < 0.01 - - -.
Other variables
Female (=0/1) −0.06 0.29 - - -
Age (years) 0.00 0.13 - - -.
Constant 6.67 < 0.01 - - -.
Note: All reported marginal effects for keratinocyte cancer were statistically significant (p-value < 0.05).
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Table 3 Costs of medical care used utilised by individuals with KC
Estimated mean costs Observed total costs
Costs categories Costs (AU$) [95% CI] Method Costs (AU$) Source
Category (1) 231 [217 to 244]
Xk
i¼1
Cat1=n 459,664 See Table 1
Category (2) 436 [240 to 632]* Cat. (1 + 2) - Cat. 1 643,993 See Table 4
Category (1 + 2) 667 [470 to 863] GLM
Category (3) 386 [47 to 725]* Correlated with KC - Cat. (1 + 2)
















n = Number with KC.
m = Number without KC.
k = Number of Category 1 services.
*The 95% CI for the difference between two means (ā and b) was estimated by  1:96 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
SE 2aþ SE 2b
q
[41].
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or Category 1 costs account for 22% of total costs. A de-
tailed enumeration of these costs is reported in Table 1.
Other generic treatments of KC or Category 2 costs ac-
count for 41% of the total. The principal cost components
are approximately medical attendance fees 10.1%, other
surgical costs 10.2%, anaesthetic fees 2.8% and pathology
8.9%. Other unspecified services contribute a further 9.3%
to total costs. The cost of correlated comorbidities ac-
counts for 37% of the total cost.
Discussion
The medical record is comprised of a complex array
of clinical data, which if available, can enhance the
quality of analysis in health research. For this work,
we utilised an administrative dataset to reconstruct
the medical record of a sample of study participants
from first principals. Our motivation was to estimate
and identify the direct and associated costs of treating
KC. Including controls for the medical record enabled
the cost of KC treatment to be estimated. We identi-
fied 16 comorbidities of interest. Each comorbidity
was identified by a list of diagnostic, medical, surgical
and pharmacological item codes associated with the
treatment of that disease. Multivariate regression was
used to generate an estimate of cost, which controlled
for the patient’s medical record with 16 dichotomous
covariates.
The decision to identify three categories of medical costs
was motivated by our desire to provide a more compre-
hensive description of the medical treatments utilised by
patients with KC, than is currently available in the litera-
ture. Whereas Fransen et al. utilised a minimalist defin-
ition of KC, where a “treatment” was defined by 37Category 1procedures directly associated with KC exci-
sion, our method has included Category 2 procedures
in the analysis. Results derived from our GLM suggest
that 12 months of KC treatment cost AU$667 per pa-
tient. Given a national age-standardised rate (ASR) of
3,271 KC services per 100,000 people [7], the implied
cost of MBS services to the nation is AU$228 million
per yearb, is considerably higher than AU$93.5 million
reported by Fransen et al. [7].
Category 2 costs were found to account for 65% (AU
$436) of the total KC treatment (AU$667). The robust-
ness of this result was tested by constructing an ad hoc
tabulation of medical services we could attribute to the
treatment of KC. In addition to the Category 1 services,
we could identify three distinct sub-groups of Category 2
costs, which were utilised by the KC cohort. Firstly, AU
$191,000 was spent on reconstructive surgeries. Localised
disfigurement is often a consequence of KC. Secondly, an
additional AU$167,000 was spent on pathology. Histolo-
gical examination of excised tissue plays a pivotal role in
differentiating benign and malignant KC and therefore we
believe that a significant proportion of these costs were
due to KC. Thirdly the KC cohort consumed an additional
AU$453,623 in medical fees.
While not all medical fees can be attributed to the
treatment of KC, a pro rata adjustment implied by our
GLM model, suggests that at least 63% [i.e. (667/1053)
*100] of these medical fees were incurred managing KC.
The surgical management of KC vis-à-visc correlated
comorbidities is likely to be labour intensive as surgical
management in the ambulatory setting can require sep-
arate appointments to diagnose biopsy, treat and provide
follow-up care, unlike medical conditions, which can be
diagnosed and treated within a single appointment.
Table 4 Potential category 2 costs
Frequencies
MBS schedule service description KC = 1 KC = 0 Difference Mean cost (AU$) Total cost (AU$)
Reconstructive surgeries
Single stage local flap 167 9 158 404 63,832
Free grafting 72 7 65 552 35,880
Lip, eyelid or ear, full thickness wedge 17 1 16 393 6,288
H-Flap or double advancement flap 16 1 15 351 5,265
Vermilionectomy 5 1 4 511 2,044
Whole thickness reconstruction of eyelid 1 0 1 846 846
Tumor, cyst, ulcer or scar removal 510 139 371 107 39,697
Lens replacement 30 23 7 1553 10,871
Premalignant skin Lesions 678 170 508 32 16,256
Neoplastic skin lesions 244 63 181 56 10,136
Pathology
Histology 1915 332 1583 104 164,632
Microscopy and culture of skin 110 33 77 32 2,464
Medical fees
Medical fees 6685 4234 2451 60 147,060
Initial or subsequent visit to specialist 4111 2250 1861 104 193,544
Anaesthetic for procedures on skin 102 19 83 300 24,900
Pre anaesthetic consult 491 319 172 336 57,723
Radiation Oncology 337 133 204 149 30,396
Note: Service definitions: MBS item numbers.
Medical attendance fees: 3, 23, 36, 44, 193, 197, 199, 2501, 2503, 2504, 2517, 2521, 2525, 2546, 2552, 5000, 5020, 5040, 5060, 86014.
Initial or subsequent visit to specialist: 104, 105, 110, 116.
Anaesthetic procedures on skin: 20100, 20160, 20300, 20400, 20420, 20700, 20800, 20820, 20900, 21110, 21460, 21600, 21800.
Pre-Anaesthetic consults: 17640, 17645, 17650, 17655, 17680, 17610, 17615, 17620, 17625, 17640, 17645, 17650, 17655, and 17680.
Radiation Oncology: 15269, 15248, 15251, 15257, 15260, 15263, 15266, 15272, 15705.
Single stage local flap: 45200, 45203, 45206, 45000, 45003.
Free grafting: 45400, 45403, 45439, 45442, 45445, 45448, and 45451.
Lip, eyelid or ear, full thickness wedge: 45665.
H-flap or double advancement flap: 45207.
Vermilionectomy: 45668, 45669.
Whole thickness reconstruction of eyelid: 45614.
Tumour, cyst, ulcer or scar removal: 31200, 31205, 31210, 31215, 31220, 31225, 31230, 31235, 31240, 52045.
Lenses replacement: 42702.
Premalignant skin lesions: 30192.
Neoplastic skin lesion: 30195.
Histology: 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836, 72838.
Microscopy and culture of skin: 69306.
Abbreviations: Medical Benefits Schedule (MBS), Keratinocyte Cancer (KC).
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$644,000 (74%) of the Category 2 costs implied by the
GLM estimate can readily be identifiedc.
A strength of this study was our utilisation of data from
a matched population-based sample of individuals linked
to an administrative cost dataset supplied by the Depart-
ment of Health, Australian Government. Our decision to
control for medical history was justified because the distri-
bution of comorbid disease was not randomly distributed
amongst cases and controls. Treatment rates for hyperten-
sion (18.5% vs. 15.9%), colorectal cancer (8.5% vs. 6.1%)
and prostate cancer (6.9% vs. 5.1%) were higher for indi-
viduals treated for KC. As a result, a large proportion ofthe comorbities were statistically significant. For individ-
uals who received treatment for one of the 16 comorbidi-
ties the marginal effect of a KC was greater than the
mean (AU$667). Patients with other cancer diagnoses
(e.g. melanoma, breast, colorectal and prostate) had KC
costs about AU$300 (45%) higher than those without. Fur-
thermore, each additional year of life increased the mar-
ginal cost of KC treatment by AU$3.30 per year.
A recently published paper by Ong et al. [42] analysed
the ICD-10 codes included in 8 million medical records
from the United Kingdom. In patients aged 45–69 years,
they report the relative risks of being treated for melan-
oma (9.4), breast cancer (1.25), prostate cancer (1.21),
Figure 1 The costs of treating individuals with KC (Total cost AU$1,053).
Rowell et al. Health Economics Review  (2015) 5:4 Page 10 of 11colon cancer (1.30) and rectal cancer (2.59) given a diag-
nosis of KC, which closely correspond to our estimates
for melanoma (14.73), breast cancer (1.24), prostate can-
cer (1.37) and colorectal cancer (1.38)d. This suggests
that the analysis of medical invoices can offer an accur-
ate insight into the patients’ medical history.
Our study has a number of limitations. While our study
collected administrative data that is likely to be compre-
hensive in most medical services for KC, other omitted
costs to the health system will underestimate our figures.
We did not have access to linked data for non-Medicare
services, the inpatient costs for a hospital admission or
other community services. Nor did our survey data in-
clude out-of-pocket expenses or indirect costs related to
interruptions to employment associated with treatments.
Furthermore, the sample includes individuals from one
state of Australia with very high rates of skin cancer and
preventive behaviour may differ from elsewhere. In
Queensland, the per patient costs for treating KC may
be minimised through the predominance of care deliv-
ered in office-based GP clinics and dedicated GP-run
skin cancer clinics. The principal methodological limita-
tion of our approach remains the exclusion of other
relevant comorbidities from our statistical models. If
relevant, the non-inclusion of these variables is likely to
result in an over estimation of the Category 2 costs as-
sociated with treating KC and an underestimation of the
Category 3 costs of comorbidities correlated with KC.
Conclusion
The methodology used in this paper has a much broader
application than estimating the costs of KC. Being able
to control for confounding effects within an individual’s
medical history can enhance empirical analysis inhealthcare. In this paper, medial service codes were uti-
lised to reconstruct a medical record from first princi-
ples. These data have greatly enriched the breadth of our
analysis, thus enabling further examination and report-
ing of a much richer description of the determinants of
cost.
Endnotes
aOur list of 42 MBS codes contained all of the 37
codes identified by Fransen et al. [7].
b-Age Standardised Rate (ASR) of KC services per
100,000 in 2011 = 3,271 [6].
- Population = 22,319,006 [6].
- MBS subsidy per 12 month KSC treatment = AU$518
(i.e. 667 * 0.777) (QSkin).
- KSC treatments per year = 1.66 (QSkin).
- ASR/100,000 * Population* MBS subsidy/ KSC treat-
ments per year = AU$228 m.
cAU$191,115 + AU$167,096 + (0.63 * AU$453,623) =
AU$643,933.
dA complete set of estimated relative risks for each
comorbidity are available from the corresponding author
upon request.
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